A share price of Biomarin Pharmaceutical Inc [BMRN] is currently trading at $54.93, up 4.29%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BMRN shares have gain 4.59% over the last week, with a monthly amount glided 4.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biomarin Pharmaceutical Inc [NASDAQ: BMRN] stock has seen the most recent analyst activity on November 06, 2025, when Stifel downgraded its rating to a Hold but kept the price target unchanged to $61 for it. Previously, H.C. Wainwright started tracking the stock with Neutral rating on September 08, 2025, and set its price target to $60. On September 03, 2025, Raymond James initiated with a Outperform rating and assigned a price target of $85 on the stock. Oppenheimer upgraded its rating to a Outperform but $98 remained the price target by the analyst firm on February 24, 2025. Wolfe Research started tracking with a Outperform rating for this stock on November 15, 2024, and assigned it a price target of $95. In a note dated October 30, 2024, William Blair downgraded an Mkt Perform rating on this stock.
Biomarin Pharmaceutical Inc experienced fluctuations in its stock price throughout the past year between $50.76 and $73.51. Currently, Wall Street analysts expect the stock to reach $82.45 within the next 12 months. Biomarin Pharmaceutical Inc [NASDAQ: BMRN] shares were valued at $54.93 at the most recent close of the market. An investor can expect a potential return of 50.1% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
Trailing Twelve Months sales for Biomarin Pharmaceutical Inc [NASDAQ:BMRN] were 3.09B which represents 5.98% growth. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.22%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.09 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.53 points at the first support level, and at 52.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 55.65, and for the 2nd resistance point, it is at 56.37.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biomarin Pharmaceutical Inc [NASDAQ:BMRN] is 4.83. In addition, the Quick Ratio stands at 3.10 and the Cash Ratio stands at 1.57. Considering the valuation of this stock, the price to sales ratio is 3.42, the price to book ratio is 1.74 and price to earnings (TTM) ratio is 20.58.
Transactions by insiders
Recent insider trading involved Burkhart Erin, GVP, Chief Accounting Officer, that happened on May 20 ’25 when 1786.0 shares were sold. Officer, Burkhart Erin completed a deal on May 20 ’25 to buy 1786.0 shares. Meanwhile, EVP, Chief Commercial Officer Hubbard Cristin sold 273.0 shares on May 02 ’25.
